Clinical trials: Risk Factor, Cardiovascular
- Condition Risk Factor, Cardiovascular
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ASCVD, Risk Factor, Cardiovascular
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy…
- Conditions
- ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol
- Trial name
- ORION-11 (NCT03400800)
- Testing
- Inclisiran Sodium
- Where
- 70 sites in Czechia, Germany and 5 more
- Volunteers
- 1,617 people
- Sponsor
- The Medicines Company
Diabetes Mellitus, Type 2, Cardiovascular Diseases
CANVAS - CANagliflozin cardioVascular Assessment Study
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE).
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Trial name
- CANVAS (NCT01032629)
- Testing
- Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Where
- 305 sites in United States, Argentina and 23 more
- Volunteers
- 4,330 people
- Sponsor
- Janssen Research & Development, LLC